Welcome to our dedicated page for Nexgel SEC filings (Ticker: NXGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NexGel, Inc. filings document the formal disclosures of a Nasdaq-listed operating company focused on hydrogel-based healthcare, beauty and OTC products. Recent 8-K reports cover material definitive agreements, an exclusive license and asset purchase for regenerative biomaterial products, convertible-note financing, and capital-structure terms tied to common stock, notes and warrants.
The filings also record board and financial officer changes, employment and compensation arrangements, Nasdaq listing-compliance notices, Regulation FD communications, and exhibits to material contracts. These disclosures connect NexGel’s product expansion, financing activity, governance structure and public-company reporting obligations.
Form 144 notice for proposed sale of common stock. The filing shows 35,515 shares of common stock are proposed for sale through The Charles Schwab Corporation, with an aggregate market value of $108,451 and 8,067,580 shares outstanding. The securities were acquired as compensation on 02/15/2024 in a transaction described as "COMPENSATION / DEAL ACQUIRED BETWEEN: 2/15/24 TO 11/5/24" and payment is recorded as of 02/15/2024. The filer reports no securities sold during the past three months. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.